Leveraging Data-Driven Insights to Improve the Health Experience for Patients Starting and Staying on Treatment

Abstract

Patients face significant challenges throughout their treatment journey, including barriers to medication access and difficulties maintaining adherence. This industry insight presents an innovative shift from retrospective, reactive patient support to a proactive, real-time, data-driven model that enables precision engagement strategies delivering the right support at the right time. This work highlights how Otsuka Precision Health leverages its robust data platform to generate insights that inform individualized patient experiences. The core innovation lies in real-time integration of pharmacy claims, support cases, and payer information, which distinguishes this approach from traditional reactive support models. These insights empower Field Support Representatives to collaborate with patients and healthcare teams, to proactively improve access, adherence, and continuity of care. By addressing healthcare system complexities and patient challenges, Otsuka Precision Health Patient Services creates a more patient-centered model that streamlines treatment initiation and sustains adherence, ultimately enhancing health outcomes.

Introduction

Patients starting a new treatment often face access barriers such as insurance delays, high out-of-pocket costs, or uncertainty about next steps. These challenges can disrupt care and reduce adherence, with negative impacts on experience and outcomes. Predictive analytics can help identify patients at risk for nonadherence and enable timely support. In chronic conditions, data-driven interventions have been associated with adherence improvements of up to 30%.^1,2 Value-based healthcare models increasingly emphasize the importance of precision engagement strategies that leverage real-time data to optimize patient outcomes while reducing healthcare costs.^3,4

Otsuka Precision Health developed a real-time data platform. Unlike traditional patient support models that rely on retrospective data and reactive interventions, this platform represents a core innovation: the real-time integration of pharmacy claims, support case records, and payer information. The system detects early signs of treatment disruption before they impact patient care. When an Insight-to-Action (I2A) alert is triggered, a Field Support Representative (FSR) proactively intervenes by coordinating with patients, providers, and pharmacies to resolve issues before care is interrupted.

This industry insight highlights Otsuka Precision Health implementation of the model, operational improvements observed, and implications for enhancing patient support and treatment continuity.

Actionable Insights

Understanding Patient Barriers

Patients experience a range of barriers that can hinder medication access and adherence, including:

Administrative delays such as prior authorization and insurance coverage issues, which can leave patients waiting weeks before therapy starts^1,2;

Financial challenges including high out-of-pocket costs and limited awareness of assistance programs^3,4;

Logistical difficulties with specialty pharmacy shipments ⁵ ; and

Behavioral and educational barriers like limited treatment understanding, forgetfulness, and concerns about side effects.^6,7

These barriers create significant disruptions to treatment continuity, impacting both patient experience and health outcomes.

From Data Integration to Proactive Intervention

Otsuka Precision Health data platform integrates pharmacy records, payer information, claims data, and patient support interactions to identify these barriers early by tracking missed refills and delayed medication use. When real-time indicators trigger an I2A alert, FSRs proactively intervene by coordinating across insurance, pharmacies, providers, and patients.

Patient Vignette: Real-World Impact of Proactive Intervention

Consider the case of Maria, a 52-year-old patient with a chronic condition who was prescribed a specialty medication. The I2A system detected that her insurance prior authorization had been pending for 5 days without resolution. Before the platform implementation, Maria would have become aware there was a delay in her prescription when the pharmacy or provider contacted her. Instead, the real-time alert triggered immediate FSR outreach and expedited necessary next steps. The FSR contacted Maria's insurance provider, identified missing documentation, coordinated with her physician's office to submit the required forms, and enrolled Maria in a bridge program to ensure she received her first dose while authorization was pending.

This proactive intervention prevented what could have been a 3- to 4-week treatment delay, reducing Maria's anxiety and maintaining her treatment momentum.

Practical Recommendations

Tailored FSR Interventions in Practice

Research demonstrates that barriers to medication access often lead to treatment disruptions, increased hospitalization, and disease progression, ⁵ while patient education and personalized support can improve adherence by approximately 30%, reducing costs and improving clinical outcomes. ⁶ Data-driven patient support approaches have shown improved engagement and satisfaction. ⁷ Digital health interventions utilizing predictive analytics have demonstrated cost-effectiveness in managing chronic diseases, with return on investment ranging from 2:1 to 5:1 through reduced hospitalizations and improved medication adherence. ⁸

Once flagged by the data platform, Otsuka Precision Health FSRs initiate high-touch, tailored interventions designed to address specific patient barriers These include:

Insurance navigation: Support with prior authorizations, appeals, and benefit verification;

Appeals, and besolutions: Enrollment in financial assistance or copay offset programs;

Pharmacy coordination: Resolving shipment delays or bridging gaps between prescription and delivery;

Provider engagement: Alerting healthcare provider (HCP) offices to missing documentation or access delays;

Patient and caregiver education: Explaining treatment plans, setting expectations, and reducing confusion; and

Digital assistance: Onboarding patients to the support website or chatbot for ongoing engagement.

FSRs use a near-real-time case management tool to prioritize outreach and document outcomes, ensuring interventions are timely and tailored to patient needs.

Implementation and Engagement Framework

Patients and caregivers (when desired) choose to opt-in to support services. For those who do not directly engage, FSRs work with HCPs and pharmacies behind the scenes to resolve access challenges, ensuring care continuity regardless of direct patient participation.

This approach transforms traditional patient support by integrating data insights with personalized interventions, requiring coordination across HCPs, pharmacies, payers, and patients to ensure sustained engagement and optimal outcomes.

Quantifying and Maximizing Impact Through Data-Driven Patient Support

Before the platform launch, FSRs relied primarily on retrospective pharmacy claims and support program data, which often led to interventions only after medication delays or missed refills had occurred. The platform's real-time data integration enables earlier and more proactive identification of patient needs (Table 1).

Table 1.

Comparison of Patient Support Metrics Before and After Data Platform Implementation.

Metric	Preplatform average	Postplatform average
Active patients/month	6317 ± 413	7738 ± 429
Percentage of flagged I2A	27.0%	25.7%
Percentage of I2A with case created	11.3 ± 1.1%	17.0 ± 2.4%
Percentage with shipment in 30 days	39.5 ± 1.5%	40.2 ± 1.5%

Note: Metrics reflect averages ± standard deviations where applicable.

Abbreviation: I2A, Insight-to-Action.

The impact analysis utilized Otsuka Precision Health centralized data platform, with proprietary algorithms continuously capturing medication fulfillment and adherence data while flagging potential barriers. The historical I2A dataset links pharmacy records with support cases, enabling analysis of interventions alongside subsequent dispensations. Data collected from August 2023 through November 2024, following the platform's July 2023 deployment, demonstrate personalized support with close monitoring of medication shipments within 30 days of case initiation.

These results focus on I2A cases from a single therapy monitored through the data platform and illustrate the range of patient barriers encountered throughout the treatment journey.

Building Data Infrastructure for Precision Engagement

Patient support cases are linked to I2A states during active treatment, with shipment tracking within 30 days of case creation. The data reveal a clear operational transformation:

Preplatform deployment (April 2022-July 17, 2023): An average of 6317 active patients were supported monthly, with 27% meeting I2A criteria. However, only 11.3% of these flagged patients had support cases opened, and 39.5% received medication shipments within 30 days—often after delays had already occurred.

Postplatform deployment (August 2023-November 2024): Patient volume increased to an average of 7738 monthly, with 25.7% meeting I2A criteria. Of these, 17% had support cases opened—representing a substantial increase in proactive engagement.

Translating Metrics into Patient Impact

This 50% relative increase in case creation (from 11.3% to 17.0%) means approximately 400 additional patients per month received personalized outreach before care disruptions occurred. For patients, this translates to reduced anxiety about treatment access, prevention of disease exacerbations, and improved quality of life. The 0.7 percentage point increase in timely shipments, while modest, represents approximately 54 additional patients monthly who maintained treatment continuity, potentially preventing costly emergency interventions or hospitalizations. FSRs were able to resolve insurance issues, coordinate with pharmacies, and provide timely education. As a result, a higher percentage (40.2%) received shipments within 30 days, reflecting improved continuity of care.

These patterns suggest improved intervention timing and shipment consistency following platform implementation.

Limitations

Patient engagement varies, as not all individuals opt-in to support services or respond consistently to outreach, which limits the generalizability of these findings given the nature of this self-selected population. Importantly, however, the opt-in process remained consistent before and after the platform's implementation, reducing the likelihood that observed differences are due to selection bias across time periods. The current findings are based on a single therapy for a chronic condition, which may limit generalizability to other treatments or patient populations. In addition, other unmeasured variables—such as operational changes or seasonal patterns—may have influenced outcomes. The analysis is descriptive and exploratory; future research should include inferential statistics to validate findings and evaluate their broader applicability.

Scaling these personalized interventions also requires sustained resource investment and coordination across stakeholders. Future research should evaluate the return on investment (ROI) of this support model, as initial resource demands may be offset by long-term cost savings from improved adherence and reduced treatment delays.

Conclusion

Integrating data-driven insights with patient support services represents a transformative step toward improving both patient outcomes and healthcare delivery. Otsuka Precision Health dynamic, patient-centered model identifies and addresses treatment barriers through timely, personalized interventions.

A robust data platform empowers FSRs to take proactive, evidence-based actions that streamline care pathways and deepen patient engagement. By converting real-time data into actionable strategies, Otsuka Precision Health facilitates smoother transitions from diagnosis to treatment and supports sustained adherence.

This model offers a blueprint for building more connected, cost-effective, and personalized healthcare systems through collaboration between providers and pharmaceutical companies. Future research should formally measure patient and provider experience through surveys and focus groups to complement the operational metrics presented here.

Ultimately, the shift toward precision health will help ensure that care is timely, equitable, and sustainable—addressing today's access and adherence challenges while setting the stage for more effective treatment journeys in the future.